Boone Capital Management Invests in uniQure Biotech

Firm buys nearly 150,000 shares of gene therapy company

Mar. 15, 2026 at 8:58am

Got story updates? Submit your updates here. ›

Boone Capital Management LLC, an investment firm based in Boone, Iowa, has acquired a new stake in uniQure N.V., a biotechnology company focused on developing gene therapies. According to a recent SEC filing, Boone Capital bought 147,317 shares of uniQure stock, valued at approximately $8.6 million, making it the firm's 14th largest holding.

Why it matters

This investment by Boone Capital Management highlights growing investor interest in uniQure and the broader gene therapy sector. As one of the first gene therapies for a bleeding disorder to reach the market, uniQure's lead product Hemgenix has generated significant attention. Boone Capital's stake represents about 0.24% of uniQure's outstanding shares.

The details

Boone Capital Management, a private investment firm based in Boone, Iowa, disclosed the new uniQure investment in a recent 13F filing with the SEC. The firm bought 147,317 shares of the biotechnology company's stock during the third quarter. This stake is valued at around $8.6 million, making uniQure Boone Capital's 14th largest holding and accounting for 2.8% of the firm's overall portfolio.

  • Boone Capital Management bought the uniQure shares during the third quarter of 2026.

The players

Boone Capital Management LLC

A private investment firm based in Boone, Iowa that manages a diversified portfolio of public and private investments.

uniQure N.V.

A biotechnology company focused on developing gene therapies, including its lead product Hemgenix which was recently approved for treating hemophilia B.

Got photos? Submit your photos here. ›

The takeaway

Boone Capital Management's investment in uniQure reflects growing institutional interest in the gene therapy space, particularly as companies like uniQure bring novel treatments to market. This deal highlights how smaller regional investment firms are also actively participating in the biotech sector's evolution.